Ascendis Pharma SEC Filings

Ascendis Pharma A/S furnished its Articles of Association as an exhibit to the Form 6-K and stated that those articles are to be incorporated by reference into multiple registration statements, specifically a series of S-8 filings and two Form F-3 filings listed in the report. The exhibit is signed by the company’s Executive Vice President, Chief Legal Officer to confirm the submission. This report supplies corporate governance documentation for use in the company’s existing registration statements and related prospectuses.

Form 144 filing for Ascendis Pharma A/S (ASND) shows proposed and recent officer-related sales of American Depositary Shares (ADS). The filing lists a proposed sale of 5,000 ADS through Merrill Lynch on 09/09/2025 with an aggregate market value of $1,018,503.05. The 5,000 ADS were acquired on 09/09/2025 via warrant exercise from Ascendis Pharma A/S and paid for in cash the same day. The filer also reported a sale on 08/13/2025 of 10,000 ADS for gross proceeds of $1,913,224.99. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer.

Insider notice of proposed sale under Rule 144 for Ascendis Pharma A/S (ASND). The filing shows 5,000 American Depositary Shares acquired via warrant exercise and to be sold through Merrill Lynch on NASDAQ with an aggregate market value of $965,000. The filer previously sold 9,375 ADS for $1,826,403.05 earlier in August. The filing discloses the acquisition method (warrant exercise), the broker, the number of shares outstanding (60,454,589) and that payment for the exercised ADS was in cash. The signer also represents they have no undisclosed material adverse information about the issuer.

Form 144 notice for Ascendis Pharma A/S (ASND) shows an intended sale of 3,036 American Depositary Shares through Merrill Lynch on NASDAQ with an aggregate market value of $588,814.29 and an approximate sale date of 08/27/2025. The shares were acquired on 09/21/2023 by warrant exercise from Ascendis Pharma A/S for cash. The filing also discloses a separate sale by Lotte Sonderbjerg of 25,000 ADS on 08/14/2025 generating gross proceeds of $4,789,998.27. The filer affirms no undisclosed material adverse information and includes the standard signature and attestation language.

Ascendis Pharma A/S (ASND) filing a Form 144 notifies the market of a proposed sale of 3,000 American Depositary Shares with an aggregate market value of $578,385. The shares represent part of 55,635,376 shares outstanding and are scheduled for sale on 08/20/2025 through Goldman Sachs & Co. LLC. The filer reports acquisition of the 3,000 ADS on 08/20/2025 via warrant exercise and payment in cash. The filing states there were no sales by the filer in the prior three months and includes the standard Rule 144 representation about no undisclosed material adverse information.

Ascendis Pharma A/S (ASND) filed a Form 144 notifying the proposed sale of 9,375 American Depositary Shares on 08/15/2025 through Merrill Lynch on NASDAQ. The filing reports an aggregate market value of $1,826,403.05 and total shares outstanding of 60,454,589. The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S, with cash payment. The filer reports no securities sold in the past three months. The notice includes the standard signature representation that the seller is not aware of any undisclosed material adverse information.

Form 144 notice for Ascendis Pharma A/S (ASND): The filer proposes to sell 25,000 American Depositary Shares on 08/14/2025 through Merrill Lynch on NASDAQ. The aggregate market value of the proposed sale is $4,789,998.27. The shares were acquired the same day on 08/14/2025 by warrant exercise from Ascendis Pharma A/S and paid in cash. The filing reports 60,454,589 shares outstanding and indicates no securities sold in the past three months by the account. The notice includes the seller's certification that no undisclosed material adverse information is known.